These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 17510432)

  • 21. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
    Zhang T; Sentman CL
    J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NKG2D ligands: key targets of the immune response.
    González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
    Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomes and the MICA-NKG2D system in cancer.
    Clayton A; Tabi Z
    Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
    Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
    Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
    Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
    Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innate immune recognition and suppression of tumors.
    Hayakawa Y; Smyth MJ
    Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.
    Sáez-Borderías A; Gumá M; Angulo A; Bellosillo B; Pende D; López-Botet M
    Eur J Immunol; 2006 Dec; 36(12):3198-206. PubMed ID: 17109473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the NKG2D receptor for tumor immunity.
    Coudert JD; Held W
    Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NKG2D and cytotoxic effector function in tumor immune surveillance.
    Hayakawa Y; Smyth MJ
    Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depletion of gammadelta T cells exacerbates murine adriamycin nephropathy.
    Wu H; Wang YM; Wang Y; Hu M; Zhang GY; Knight JF; Harris DC; Alexander SI
    J Am Soc Nephrol; 2007 Apr; 18(4):1180-9. PubMed ID: 17329577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
    Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
    Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer.
    Osaki T; Saito H; Yoshikawa T; Matsumoto S; Tatebe S; Tsujitani S; Ikeguchi M
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):382-7. PubMed ID: 17255258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
    Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
    Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
    Groh V; Smythe K; Dai Z; Spies T
    Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-specific T cells combine proliferation and antitumor activity.
    Kershaw MH; Westwood JA; Hwu P
    Nat Biotechnol; 2002 Dec; 20(12):1221-7. PubMed ID: 12415288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients.
    Wang H; Yang D; Xu W; Wang Y; Ruan Z; Zhao T; Han J; Wu Y
    Immunol Lett; 2008 Oct; 120(1-2):65-71. PubMed ID: 18672004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions.
    Allez M; Tieng V; Nakazawa A; Treton X; Pacault V; Dulphy N; Caillat-Zucman S; Paul P; Gornet JM; Douay C; Ravet S; Tamouza R; Charron D; Lémann M; Mayer L; Toubert A
    Gastroenterology; 2007 Jun; 132(7):2346-58. PubMed ID: 17570210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.